These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21982342)

  • 1. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.
    Wu YL; Park K; Soo RA; Sun Y; Tyroller K; Wages D; Ely G; Yang JC; Mok T
    BMC Cancer; 2011 Oct; 11():430. PubMed ID: 21982342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.
    Ohyanagi F; Horai T; Sekine I; Yamamoto N; Nakagawa K; Nishio M; Senger S; Morsli N; Tamura T
    Jpn J Clin Oncol; 2011 May; 41(5):718-22. PubMed ID: 21393255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
    J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.
    Butts C; Maksymiuk A; Goss G; Soulières D; Marshall E; Cormier Y; Ellis PM; Price A; Sawhney R; Beier F; Falk M; Murray N
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1337-42. PubMed ID: 21744082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
    Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
    Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
    Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
    BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.
    Butts C; Murray RN; Smith CJ; Ellis PM; Jasas K; Maksymiuk A; Goss G; Ely G; Beier F; Soulières D
    Clin Lung Cancer; 2010 Nov; 11(6):391-5. PubMed ID: 21071331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
    Sangha R; Butts C
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer.
    Thatcher N; Heighway J
    Oncologist; 2010; 15(10):1034-42. PubMed ID: 20930098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
    Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
    Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
    Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
    Wu YL; Kim JH; Park K; Zaatar A; Klingelschmitt G; Ng C
    Lung Cancer; 2012 Aug; 77(2):339-45. PubMed ID: 22494567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.
    Wurz GT; Gutierrez AM; Greenberg BE; Vang DP; Griffey SM; Kao CJ; Wolf M; DeGregorio MW
    J Transl Med; 2013 Mar; 11():64. PubMed ID: 23496860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    Reck M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers.
    North S; Butts C
    Expert Rev Vaccines; 2005 Jun; 4(3):249-57. PubMed ID: 16026241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
    Mehta NR; Wurz GT; Burich RA; Greenberg BE; Griffey S; Gutierrez A; Bell KE; McCall JL; Wolf M; DeGregorio M
    Clin Cancer Res; 2012 May; 18(10):2861-71. PubMed ID: 22434666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
    Quoix E; Ramlau R; Westeel V; Papai Z; Madroszyk A; Riviere A; Koralewski P; Breton JL; Stoelben E; Braun D; Debieuvre D; Lena H; Buyse M; Chenard MP; Acres B; Lacoste G; Bastien B; Tavernaro A; Bizouarne N; Bonnefoy JY; Limacher JM
    Lancet Oncol; 2011 Nov; 12(12):1125-33. PubMed ID: 22019520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
    Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
    Front Immunol; 2018; 9():2145. PubMed ID: 30283461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.